Epigenetics is the study of changes in gene expression patterns due to mechanisms other than mutations in the underlying DNA sequence. Epigenetic modifications are inherited by daughter cells during cell division. The changes in gene expression associated with epigenetics are governed by alterations in chromatin structure.
Related Topics: Mutational Analysis, Gene Cloning and Analysis, Gene Expression Analysis, and Nucleic Acid Analysis.
In the nucleus, DNA is associated with a class of structural and regulatory proteins called histones. The nucleosome refers to the units of DNA spooled around histone complexes, typically structured as heterotetramers (two copies of four different histone proteins). Stretches of DNA between individual nucleosomes are referred to as linker DNA. The highly ordered packaging of DNA and histones together is called chromatin.
Storage of DNA. The DNA in the nucleus of the cell is complexed in a very orderly fashion with a class of structural and regulatory proteins called histones. The combination of histones and DNA together is called chromatin.
Structure of Chromatin. Chromatin consists of DNA spooled around complexes of histone protein molecules called nucleosomes.
Chromatin structure influences the accessibility of promoter regions to transcription factors. The accessibility, or lack of accessibility, of promoter DNA represents a major means of transcriptional regulation and is at the center of epigenetic gene regulation. Relaxed chromatin, also known as euchromatin, allows transcription factors more ready access to promoter sites, thereby facilitating activation of transcription. In contrast, heterochomatin is densely compacted to varying degrees, often concealing DNA promoter sequences from potential transcription factors. Epigenetic markers (or marks) are the modifications to histone proteins and DNA that modulate the affinity of chromatin-binding proteins, in turn altering chromatin structure.
Researchers are interested in understanding the role of epigenetics in disease progression. The activity of enzymes that modify histones can be affected by environmental factors, such as toxins or stress, leading to alterations in gene transcription. Aberrant methylation has been well correlated with gene silencing and the development of several cancers.
Biomedical research is exploring if epigenetic regulations can be exploited for the development of novel drug therapies. For example, abnormal changes in chromatin conformation associated with the development of cancer might be reversible with the proper therapeutic. Epigenetic therapies, such as manipulating the chromatin conformation of specific genes to activate or repress transcription, would appear to be far more achievable than genetic therapies requiring precise DNA sequence modifications.
Stem cell researchers are actively and aggressively exploring epigenetics. Stem cells are unique in that they have not assumed a particular cell fate and retain the potential to become a variety of tissue types — a cellular state referred to as pluripotency. Studies of the epigenetic changes that occur during stem cell differentiation have provided clues to how the epigenetic status of cells may impact pluripotency. Epigenetic manipulations may enable researchers to more accurately direct differentiation of cells into desired cell types and may aid in the generation of induced pluripotent stem cells, the practice of reprogramming fully differentiated cells back toward a state of pluripotency.
While most genes in autosomal cells are simultaneously expressed from both alleles, a small proportion of genes are expressed in a monoallelic fashion. Imprinting is the process through which one of two alleles for a given gene is silenced in a parent-of-origin specific pattern. Imprinting is considered a form of epigenetics because it leads to heritable changes in gene expression despite a lack of changes in the genomic code.
The silencing of one allele in imprinting is achieved through DNA methylation and histone modifications. Non-protein coding RNAs greater than 200 bp in length (long ncRNAs) play a role in genomic imprinting by recruiting chromatin remodeling complexes to regions of the genome that are silenced.
Genetic imprinting has been linked to the development of several diseases, including various forms of cancer. Various oncogenes and tumor suppressor genes appear to demonstrate patterns of imprinting. Given the potential role for gene imprinting in disease progression, scientists are actively investigating how epigenetic modifications impact monoallelic gene expression.
Researchers are also examining the potential for epigenetic markers to serve as biomarkers for disease. Biomarkers are diagnostic correlates that aid in the prognosis and diagnosis of diseases. Indeed, differences in epigenetic patterns between diseased and healthy tissues are apparent. Current efforts in biomarker research predominantly examine DNA methylation patterns in tissue biopsies (Laird 2010). It is possible that epigenetic changes may aid in disease diagnosis and help dictate the most appropriate therapeutic approaches for treating patients.
Ben-David U and Benvenisty N (2011). The tumorigenicity of human embryonic and induced pluripotent stem cells. Nat Rev Cancer 11, 268–277. PMID: 21390058
Carey N et al. (2011). DNA demethylases: A new epigenetic frontier in drug discovery. Drug Discov Today 16, 683–690. PMID: 21601651
Chi P et al. (2010). Covalent histone modifications — miswritten, misinterpreted, and miserased in human cancers. Nat Rev Cancer 10, 457–469. PMID: 20574448
Laird PW (2010). Principles and challenges of genome-wide DNA methylation analysis. Nat Rev Genet 3, 191–203. PMID: 20125086
Malecová B and Morris KV (2010). Transcriptional gene silencing through epigenetic changes mediated by noncoding RNAs. Curr Opin Mol Ther 12, 214–222. PMID: 20373265
Pembrey M (1996). Imprinting and transgenerational modulation of gene expression: Human growth as a model. Acta Genet Med Gemellol (Roma) 45, 111–125. PMID: 8872020
Perry AS et al. (2010). The epigenome as a therapeutic target in prostate cancer. Nat Rev Urol 7, 668–680. PMID: 21060342
Call us at 1-800-4-BIORAD (1-800-424-6723)
Please reenter your email address in the correct format.
Please enter your email address.
Your subscription information already exists, we will send you an email with specific instructions to manage your existing subscription profile.
To receive the latest news, promotions, and more, sign up for Bio-Rad updates by entering your email address below. You can elect to receive only the types of Bio-Rad communications that are of interest to you..
Copyright © 2016 Bio-Rad Laboratories, Inc. All rights reserved.